- Home
- LOGI vs MDGL Comparison
LOGI vs MDGL Comparison
Compare LOGI & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOGI | MDGL |
|---|---|---|
| Founded | 1981 | 2011 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2B | 12.0B |
| IPO Year | 1997 | 2005 |
Fundamental Metrics
Financial Performance| Metric | LOGI | MDGL |
|---|---|---|
| Price | $91.23 | $520.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | $106.75 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 880.3K | 349.8K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | ★ 1.74% | N/A |
| EPS Growth | 6.72 | ★ 41.32 |
| EPS | ★ 3.82 | N/A |
| Revenue | N/A | ★ $180,133,000.00 |
| Revenue This Year | $8.30 | $58.39 |
| Revenue Next Year | $2.68 | $47.10 |
| P/E Ratio | $23.83 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $69.19 | $265.00 |
| 52 Week High | $122.93 | $615.00 |
Technical Indicators
Market Signals| Indicator | LOGI | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 62.15 |
| Support Level | $88.18 | $411.87 |
| Resistance Level | $94.53 | $610.00 |
| Average True Range (ATR) | 2.18 | 26.99 |
| MACD | 0.06 | 3.75 |
| Stochastic Oscillator | 24.76 | 64.35 |
Price Performance
Historical ComparisonAbout LOGI Logitech International S.A.
Logitech was founded in 1981 and is headquartered in Lausanne, Switzerland. The company specializes in designing and manufacturing computer peripherals such as mice, keyboards, webcams, conference room cameras, headsets, and music-related products like wireless speakers.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.